drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (genetically modified T cells)
drug_description
Autologous TCR-T cell therapy engineered to express a high-affinity T-cell receptor recognizing an AFP-derived peptide presented by HLA-A*02:03 on tumor cells, inducing MHC-restricted T-cell activation and cytotoxic killing; administered after lymphodepleting chemotherapy to enhance engraftment, expansion, and persistence.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Adoptive Immunotherapy
drug_category
ENGINEERED TCR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a high-affinity T-cell receptor that recognizes an AFP-derived peptide presented by HLA-A*02:03 on tumor cells. Engagement of the AFP/HLA complex triggers MHC-restricted T-cell activation and cytotoxic killing via perforin/granzyme release and cytokine secretion. Lymphodepleting chemotherapy is given pre-infusion to enhance engraftment, expansion, and persistence of the infused TCR-T cells.
drug_name
HRYZ-T102 (AFP-specific TCR-engineered T cells)
nct_id_drug_ref
NCT06515314